Early study of an HER2 drug in advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a HER2-positive or HER2-expressing solid tumor (or HER2-null only for one specific group).
- Your cancer is advanced/unresectable, recurring, or metastatic, and either didn’t respond to standard treatment, can’t be tolerated, or there’s no standard option.
- You have at least one measurable tumor spot that can be tracked by scans.
- Your general health is good: ECOG performance status 0–1.
- Your heart function is strong: left heart pumping strength (LVEF) is at least 50%, and you meet related heart rhythm/QT rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This Phase 1 trial tests a combination of medicines (including DS-1103a) for people with advanced, hard-to-remove (unresectable) or metastatic solid tumors that have HER2 changes. Because it’s an early safety/dose study, it mainly aims to find the right dose and see how the tumor responds.
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Hear when a new HER2-positive Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.